What is the generic name?

DOXORUBICIN HYDROCHLORIDE LIPOSOME

What is the Trade Name for DOXORUBICIN HYDROCHLORIDE LIPOSOME?

Doxorubicin Hydrochloride Liposome

What are the Indications for DOXORUBICIN HYDROCHLORIDE LIPOSOME?

• 1 INDICATIONS AND USAGE Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: ‚Ä¢ Ovarian cancer: After failure of platinum-based chemotherapy ( 1.1 ) ‚Ä¢ AIDS-related Kaposi‚Äôs Sarcoma: After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) ‚Ä¢ Multiple Myeloma: In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) 1.1 Ovarian Cancer Doxorubicin hydrochloride liposome injection is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy. 1.2 AIDS-Related Kaposi‚Äôs Sarcoma Doxorubicin hydrochloride liposome injection is indicated for the treatment of AIDS-related Kaposi‚Äôs sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy. 1.3 Multiple Myeloma Doxorubicin hydrochloride liposome injection, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

References: https://open.fda.gov/